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A B S T R A C T
Purpose: To report on a case of recurrence of paraproteinemic keratopathy (PPK) associated with monoclonal
gammopathy after bilateral penetrating keratoplasty.
Observations: Penetrating keratoplasty was performed on both eyes of a 45-year-old man due to bilateral pro-
gressive corneal stromal clouding. Recurrence of the corneal stromal opacities accompanied by a decrease in
visual acuity was observed on slit-lamp examination already two years after penetrating keratoplasty. Confocal
laser scanning microscopy (CLSM) of the corneal grafts performed three years after penetrating keratoplasty
showed bilateral morphological changes identical to that found in the patient's corneas prior to penetrating
keratoplasty. A hematological work-up revealed monoclonal gammopathy of type IgG kappa. The histochemical
examination of the explanted corneas confirmed the diagnosis of PPK.
Conclusions and importance: Paraproteinemic keratopathy is an underdiagnosed ophthalmological condition,
which may be associated with potentially life-threatening hematologic disorders. A hematological workup
should be performed in patients with corneal opacities of uncertain etiology. Penetrating keratoplasty should be
performed with caution in patients with monoclonal gammopathy due to the possibility of a very fast recurrence
of PPK in the corneal graft. This is the first presentation of the recurrence of flake-like PPK after penetrating
keratoplasty assessed with CLSM.
1. Introduction
Paraproteinemic keratopathy (PPK) or immunotactoid keratopathy
is an umbrella term for a heterogenous group of corneal findings as-
sociated with monoclonal gammopathy. Monoclonal gammopathy is
defined as a presence of abnormal protein (paraprotein), i.e. inoperable
immunoglobulins or their parts (light or heavy chains), in the blood.
Monoclonal gammopathies include disorders as: monoclonal gammo-
pathy of undetermined significance (MGUS), smoldering multiple
myeloma (SMM) or multiple myeloma (MM).
The incidence of MGUS is as high as 3.5% in people over 50 years of
age and represents one of the most common premalignant disorders in
Western countries.1,2 MGUS may precede not only MM, but also other
potentially life-threatening diseases such as B-cell non-Hodgkin lym-
phoma or chronic myeloid leukaemia.3 According to hematological
therapy guidelines, MGUS does not require any systemic therapy, but
regular workup is needed in order to recognize its progression to MM or
other immunoproliferative disorders.4
Early recognition of PPK by an ophthalmologist may help to
diagnose some hematological disorders before a clinical progression
occurs. The deposits of paraprotein in the cornea may reveal very dis-
tinct patterns and may involve all corneal layers. Crystalline and non-
crystalline forms of PPK are known. Furthermore, PPK may imitate
systemic and/or metabolic disorders; hereditary corneal dystrophies;
inflammation or contact-lens related corneal damage. In addition to a
detailed medical history, a general medicalexamination, check-up of
family members and genetic analyses should be performed to exclude
other reasons for corneal opacity. The new classification of PPK and
detailed differential diagnoses have recently been reported by Lisch
et al.5
In vivo confocal laser-scanning microscopy (CLSM) provides an in-
sight into corneal morphology at the cellular level. Not only cells, but
also extracellular deposits may be characterized.6 The literature re-
garding CLSM findings in PPK is poor. So far it consists of only a few
case reports regarding crystalline keratopathy associated with MM and
SMM as well as one case of crystalline keratopathy in a patient suffering
from MGUS.7–10 Micali et al. presented a comparison between confocal
a histopathological changes in a patient with MM11
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This report presents a diagnostic chain, which was conducted in a
patient with bilateral corneal clouding. To the best of our knowledge,
this is the first description of a recurrence of a stromal flake-like PPK
after bilateral penetrating keratoplasty assessed with CLSM.
2. Case report
2.1. Findings prior to penetrating keratoplasty
A 43-year-old man was examined for the first time at the
Department of Ophthalmology of the University Medical Center in
Mainz in 2009 due to bilateral worsening of visual acuity and photo-
phobia. The patient's medical history was uneventful. He had never
suffered from systemic or metabolic diseases. He had never used any
systemic medication, eye drops or contact lenses. He had no history of
any ocular or refractive surgery. The family history regarding ocular
diseases was negative. At presentation, the BCVA was 0.63 in both eyes.
Slit-lamp examination revealed bilateral diffuse yellowish corneal de-
posits localized in the corneal stroma (Fig. 1). Central corneal thickness
was 543 μm in the right and 542 μm in the left eye. The intraocular
pressure (IOP) was 15mm Hg and the examination of the retina re-
vealed normal findings. Bilateral progression of corneal clouding was
accompanied by a decrease in visual acuity to 0.25 in the right and 0.16
in the left eye during the following three years. A genetic evaluation
was performed as we suspected a congenital stromal corneal dystrophy
(CSCD). However, it did not reveal any mutation in the transforming
growth factor β-induced (TGFBI) and decorin (DCN) genes. The CLSM
performed using the Heidelberg Retina Tomograph (HRT II) in con-
junction with the Rostock Cornea Module (RCM) [Heidelberg En-
gineering GmbH, Heidelberg, Germany]12 revealed rarefied keratocytes
and decreased transparency of the extracellular matrix in the anterior
stroma (Fig. 2a); loss of keratocytes and “coral” – like hyperreflective
structures in the mid stroma (Fig. 2b and c); more homogenous hy-
perreflection and obscured details in the posterior stroma (Fig. 2d).
Increased reflectivity of the stroma prevented visualization of the cor-
neal endothelium. The findings were similar in both eyes.
Non-HLA-matched penetrating keratoplasty was performed on the
left eye in March 2012. HLA-matched penetrating keratoplasty was
performed on the right eye in November 2012. The HLA-matching of
the second PKP was due to participation in the FANCY study.13 Both
keratoplasties were uneventful and fixed with double running sutures,
which were removed one year after surgery. The postoperative course
was also uneventful.
2.2. Findings after penetrating keratoplasty
A follow-up examination conducted two years after penetrating
keratoplasty revealed recurrence of the fine corneal stromal deposits. At
this time point BCVA was 0.63 in the right and 0.8 in the left eye. The
progressive corneal clouding caused decline of BCVA to 0.32 in the
right and to 0.5 in the left eye three years postoperatively. At that time
the slit lamp appearance of the corneal deposits was almost identical to
the preoperative findings (Fig. 3). The anterior segment spectral do-
main - OCT revealed homogenous hyperreflectivity of the cornea con-
sistent with the clinical features. IOP measurement and fundoscopy
revealed normal findings. At the time of the manuscript submission
BCVA declined further to 0.16 in the right and 0.32 in the left eye.
CLSM performed three years postoperatively revealed rarefied ker-
atocytes and decreased transparency of the anterior stroma (Fig. 4 a);
loss of keratocytes and “coral” – like hyperreflective structures in the
middle stroma (Fig. 4b and c) with increasing homogenous hyperre-
flection in the posterior stroma (Fig. 4d) almost identical to the pre-
operative findings. The findings were again similar in both eyes.
2.3. Hematological workup
The patient had not presented B symptoms. The first hematological
laboratory diagnostics performed as soon as stromal opacities recurred
revealed IgG, IgM and IgA within the normal range; increased free
kappa light chains by 19.7 mg/l (normal values 3.3–19.4 mg/l); in-
creased kappa-lambda quotient 4.7 (normal values 1.3–2.6). No free
light chains in the urine. The immunfixation of urine was normal. The
plasma immunfixation confirmed the diagnosis of monoclonal gam-
mopathy of type IgG kappa of intermediate-high risk.
Bone marrow biopsy presented no relevant proliferation of plasma
cells. The whole-body low-dose computer tomography did not reveal
Fig. 1. Corneal clouding in diffuse illumination (a) and in optical section (b–c). Lisch et al. Trans Am Ophthalmol Soc 2016; 114:T7 (1–21).
Fig. 2. In vivo confocal laser-scanning microscopy of the clouded cornea of the right eye before penetrating keratopasty at the depth of a) 125 μm, b) 201 μm, c) 276
μm, d) 380 μm. Arrows indicate the “coral” – like hyperreflective structures in the middle stroma.
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any osteolysis.
The most recent laboratory evaluation revealed that IgG, IgM and
IgA were still within the normal range; free kappa light chains increased
to 22.9 mg/l (normal values 3.3–19.4 mg/l); the kappa-lambda quo-
tient increased to 7.3 (normal values 1.3–2.6); M protein was at 7.8 g/l.
No free light chains were detected in the urine. The immunfixation of
urine was still normal.
2.4. Histopathology
Light microscopy of the corneal buttons revealed normal epithelium
and degenerative stromal morphology. The Congo red staining did not
reveal any amyloid deposits.
An expanded evaluation revealed: a) irregular corneal stromal de-
posits exhibiting placoid configuration (Masson's trichrome,× 136)
(Fig. 5a); b) stromal extracellular, electron-dense amorphous deposits
in between normal collagen fibrils (x 81,000) by transmission electron
microscopy (x 36,000) (Fig. 5b); c) brownish staining of stromal de-
posits with antibodies against IgG (immunoperoxidase reaction, x100)
(Fig. 5c). These findings confirmed the diagnosis of PPK.
3. Discussion
Paraproteinemic keratopathy comprises a number of corneal
clouding patterns, which are symptoms of premalignant or malignant
hematological disorders.5 These conditions are probably under-
diagnosed in the ophthalmological daily routine because they are
mistaken for corneal dystrophies or degenerations. On the other hand,
the possible presence of PPK is not incorporated in any of the hema-
tological diagnostic and therapy guidelines. Advanced corneal clouding
leading to severe visual impairment and resulting in corneal trans-
plantation is not defined as end-organ damage and the patient's
monoclonal gammopathy is still regarded as one of undetermined sig-
nificance.
It took us as long as six years to diagnose PPK and MGUS in our
patient. The finding of bilateral diffuse stromal opacities suggested a
hereditary dystrophy of the cornea, such as congenital stromal corneal
dystrophy (CSCD), which was primarily taken into consideration.
However, the clinical examination of the patient's mother and three
sisters was negative for corneal disorders. In contrast to CSCD, corneal
thickness was normal and the onset of the clinical manifestation was
late.14 There were no mutations in the TGFBI and DCN genes. Fur-
thermore, there was no indication for inflammatory, toxic or contact
lens-induced damage. The CLSM performed three years after the first
Fig. 3. Corneal clouding in diffuse illumination (a–b) and in optical section (c); hyperreflectivity of the corneal stroma in the anterior segment Spectralis optical
coherence tomography (d) of the right eye. Lisch et al. Trans Am Ophthalmol Soc 2016; 114:T7 (1–21).
Fig. 4. In vivo confocal laser-scanning microscopy of the clouded cornea of the right eye three years after penetrating keratopasty at the depth of a) 137 μm, b) 227
μm, c) 368 μm, d) 457 μm. Arrows indicate the “coral” – like hyperreflective structures in the middle stroma.
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clinical manifestation was not diagnostically helpful as there were no
published descriptions of the non-crystalline PPK assessed with CLSM.
Hence, the images of “coral”-like hyperreflective structures in the
middle and posterior stroma could not be properly interpreted.
The yellowish diffuse deposits recurred in the same morphological
pattern in both corneal grafts as soon as two years after PKP. The quick
recurrence led us once more evaluate possible systemic causes of cor-
neal clouding. The hematological workup revealed MGUS of IgG kappa
type. Under these circumstances and considering the new classification,
the proper ophthalmological diagnosis “flake-like PPK” was made.5 The
expanded histological, histochemical and electron microscopic evalua-
tion of the explanted corneal buttons confirmed deposits of im-
munoglobulins in the corneal stroma.
Our patient has been undergoing a hematological follow-up every
3–6 months in order to exclude progression to MM since MGUS was
diagnosed. The intervals of the hematological work-up depend on the
individual risk profile and are defined by the International Myeloma
Working Group.15 As we mentioned above, according to the hemato-
logical guidelines there is no indication for systemic chemotherapy at
the moment. Buerk et al. found a regression of number and size of the
corneal deposits assessed with CLSM in a patient with MM-associated
crystalline keratopathy six months after onset of chemotherapy.7
However, there are no clinical trials or case reports regarding the
outcome of MGUS-associated PPK under systemic therapy. Concerning
PPK as end-organ damage, a systemic therapy with Bortezomib and
dexamethasone has been taken into consideration, but has not yet been
applied to our patient.
CLSM of corneal grafts showed the pattern of characteristic “coral”-
like hyperreflective structures in the middle and posterior stroma
identical to that seen at the first preoperative CLSM. There were no
needle-shaped hyperreflective crystals or dendritic-shaped keratocytes,
which were seen in CLSM in cases of MM- and SMM-associated crys-
talline PPK.7–11 To the best of our knowledge, this is the first pre-
sentation of the recurrence of flake-like stromal PPK associated with
MGUS after penetrating keratoplasty assessed by CLSM.
4. Conclusions
PPK should be taken into consideration in every corneal disorder of
undetermined entity. The hematological workup induced by an oph-
thalmologist may help to diagnose premalignant or even malignant
disorders in a more timely fashion. In case of PPK, corneal transplan-
tation should be indicated with caution as a swift recurrence in the
corneal grafts is to be expected and frequent re-grafting results in in-
creased risk of immunologic graft rejection.16 Deep anterior lamellar
keratoplasty could be an alternative to PKP in case of assessable and
intact endothelium. We believe that the non-invasive and quick ex-
amination using CLSM and, most of all, the correct interpretation of the
images may lead to the proper ophthalmological and, consecutively,
hematological diagnosis.
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